低密度リポプロテイン濃度が非常に低い患者のスタチンの使用は,生存率の改善と関連しています
Nicholas J Leeper1, Reza Ardehali, Emil M deGoma
1Department of Medicine, Stanford University School of Medicine, VA Palo Alto HealthCare System, Palo Alto, Calif, USA. nleeper@cvmed.stanford.edu
Circulation
|August 1, 2007
まとめ
スタチンによる積極的な脂質管理は,冠動脈疾患の標準です. この研究では,低密度リポプロテイン (LDL) コレステロールが非常に低い患者にスタチン療法が安全で有効であることが判明し,生存率を改善しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- クリニカル・メディシン 臨床医学
背景:
- 積極的な脂質管理は,冠動脈疾患の患者の現在の標準です.
- 極低密度リポプロテイン (LDL) コレステロールレベル (<60 mg/dL) の患者におけるスタチン治療の安全性と有効性は,さらなる調査を必要としています.
研究 の 目的:
- LDLコレステロールレベルが60 mg/dL未満の患者におけるスタチン治療の安全性と臨床結果を評価する.
主な方法:
- 高等医療センターから,LDLレベル<60 mg/dLの6107人の患者を遡及的に分析した.
- スタチンの治療は,低LDLの測定から150日以内に処方されるものと定義された.
- 傾向スコアマッチングは,スタチン療法を受ける可能性に調整するために使用されました.
主要な成果:
- スタチンの治療は,診断された患者の60%に処方された (n=2564).
- 傾向スコア調整後,スタチン治療は生存率の改善 (HR,0.65;95%CI,0.53から0.80) と関連していました.
- スタチンの使用は,悪性腫瘍,トランスアミナーゼ上昇,またはラブドミオリシスのリスクを増加させませんでした.
結論:
- スタチンの治療は,非常に低いLDLコレステロールレベルを有する患者にとって安全であるようです.
- この集団におけるスタチンの治療は,生存の改善と関連しています.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...